{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T02:45:36Z","timestamp":1758595536654,"version":"3.44.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100008319","name":"Fondation Arthritis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008017","name":"Gustave Roussy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Malakoff M\u00e9d\u00e9ric"},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Using flow cytometry, we assessed circulating T4sen and T8sen proportions at baseline and 3 months after initiating anti-TNF treatment in RA and SpA patients using flow cytometry. Circulating levels of cytokines were measured at baseline. These parameters were associated with demographic variables and disease activity. T4sen and T8sen were compared between RA, SpA, SjD, healthy donors, and cancer patients. T8sen, but not T4sen, accumulated more in patients with IMIDs than in patients with lung cancer and healthy donors. CMV-seropositivity was associated with the accumulation of T8sen. T8sen were associated with high IL-6 in SpA patients and high IP-10 in SjD patients. Anti-TNF did not impact the T8sen proportion of RA and SpA patients. There was a trend toward an increase in T8sen in anti-TNF nonresponders after 3 months of treatment. Senescent CD8 T cells are enriched in IMID patients, suggesting that immune aging is a shared feature of chronic inflammatory diseases. The association between T8sen and distinct inflammatory cytokines underscores the potential role of senescence in shaping immune responses in IMIDs.<\/jats:p>","DOI":"10.1093\/cei\/uxaf050","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:44:51Z","timestamp":1753357491000},"source":"Crossref","is-referenced-by-count":0,"title":["Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokines"],"prefix":"10.1093","volume":"219","author":[{"given":"Marie","family":"Naigeon","sequence":"first","affiliation":[{"name":"INSERM US23\/CNRS UAR 3655, Laboratoire d\u2019Immunomonitoring en Oncologie, Gustave Roussy, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-2269","authenticated-orcid":false,"given":"Samuel","family":"Bitoun","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) UMR1184, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris (APHP), CEA, FHU CARE, Universit\u00e9 Paris-Saclay , Le Kremlin Bic\u00eatre,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Roulleaux Dugage","sequence":"additional","affiliation":[{"name":"INSERM US23\/CNRS UAR 3655, Laboratoire d\u2019Immunomonitoring en Oncologie, Gustave Roussy, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]},{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces (DITEP), Gustave Roussy, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"INSERM US23\/CNRS UAR 3655, Laboratoire d\u2019Immunomonitoring en Oncologie, Gustave Roussy, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Berthot","sequence":"additional","affiliation":[{"name":"INSERM US23\/CNRS UAR 3655, Laboratoire d\u2019Immunomonitoring en Oncologie, Gustave Roussy, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-8189","authenticated-orcid":false,"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Oncologique, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces (DITEP), Gustave Roussy, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Danlos","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces (DITEP), Gustave Roussy, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) UMR1184, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris (APHP), CEA, FHU CARE, Universit\u00e9 Paris-Saclay , Le Kremlin Bic\u00eatre,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Chaput","sequence":"additional","affiliation":[{"name":"INSERM US23\/CNRS UAR 3655, Laboratoire d\u2019Immunomonitoring en Oncologie, Gustave Roussy, Universit\u00e9 Paris-Saclay , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetane","family":"Nocturne","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) UMR1184, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris (APHP), CEA, FHU CARE, Universit\u00e9 Paris-Saclay , Le Kremlin Bic\u00eatre,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"2025092206061081500_CIT0001","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14737140.2022.2098718","article-title":"Immunosenescence, inflammaging, and cancer immunotherapy efficacy","volume":"22","author":"Rodriguez","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025092206061081500_CIT0002","doi-asserted-by":"publisher","first-page":"e12675","DOI":"10.1111\/acel.12675","article-title":"Human CD8+ EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK","volume":"17","author":"Callender","year":"2018","journal-title":"Aging Cell"},{"key":"2025092206061081500_CIT0003","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood-2002-02-0657","article-title":"Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)","volume":"100","author":"Voehringer","year":"2002","journal-title":"Blood"},{"key":"2025092206061081500_CIT0004","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.it.2016.09.002","article-title":"Senescence of T lymphocytes: implications for enhancing human immunity","volume":"37","author":"Akbar","year":"2016","journal-title":"Trends Immunol"},{"key":"2025092206061081500_CIT0005","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1078-0432.ccr-20-1420","article-title":"Circulating T-cell immunosenescence in patients with advanced non\u2013small cell lung cancer treated with single-agent PD-1\/PD-L1 inhibitors or platinum-based chemotherapy","volume":"27","author":"Ferrara","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025092206061081500_CIT0006","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1182\/blood-2009-01-199588","article-title":"KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells","volume":"113","author":"Henson","year":"2009","journal-title":"Blood"},{"key":"2025092206061081500_CIT0007","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cyto.a.22351","article-title":"From \u201ctruly na\u00efve\u201d to \u201cexhausted senescent\u201d T cells: when markers predict functionality","volume":"85","author":"Larbi","year":"2014","journal-title":"Cytometry A"},{"key":"2025092206061081500_CIT0008","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.12790","article-title":"T and B-cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity","volume":"291","author":"Preite","year":"2019","journal-title":"Immunol Rev"},{"key":"2025092206061081500_CIT0009","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41423-019-0344-8","article-title":"Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment","volume":"17","author":"Zhao","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025092206061081500_CIT0010","doi-asserted-by":"publisher","first-page":"eadh0708","DOI":"10.1126\/sciadv.adh0708","article-title":"Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC","volume":"9","author":"Naigeon","year":"2023","journal-title":"Sci Adv"},{"key":"2025092206061081500_CIT0011","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jcv.2016.02.010","article-title":"Significant IFN\u03b3 responses of CD8+ T cells in CMV-seropositive individuals with autoimmune arthritis","volume":"77","author":"Almanzar","year":"2016","journal-title":"J Clin Virol"},{"key":"2025092206061081500_CIT0012","doi-asserted-by":"publisher","first-page":"9121","DOI":"10.1002\/jcp.26956","article-title":"Cellular senescence: molecular mechanisms and pathogenicity","volume":"233","author":"Wei","year":"2018","journal-title":"J Cell Physiol"},{"key":"2025092206061081500_CIT0013","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.4049\/jimmunol.1301409","article-title":"IFN- Inhibits telomerase in human CD8+ T cells by both hTERT downregulation and induction of p38 MAPK signaling","volume":"191","author":"Lanna","year":"2013","journal-title":"J Immunol"},{"key":"2025092206061081500_CIT0014","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1172\/JCI12516","article-title":"CD4+CD28- costimulation-independent T cells in multiple sclerosis","volume":"108","author":"Markovic-Plese","year":"2001","journal-title":"J Clin Invest"},{"key":"2025092206061081500_CIT0015","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.clim.2007.01.005","article-title":"Analyses of immunosenescent markers in patients with autoimmune disease","volume":"123","author":"Thewissen","year":"2007","journal-title":"Clin Immunol"},{"key":"2025092206061081500_CIT0016","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.0300-9475.2004.01464.x","article-title":"CD28nullCD4+ T cells--characterization of an effector memory T-cell population in patients with rheumatoid arthritis","volume":"60","author":"Fasth","year":"2004","journal-title":"Scand J Immunol"},{"key":"2025092206061081500_CIT0017","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1196\/annals.1361.066","article-title":"Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients","volume":"1051","author":"Thewissen","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"2025092206061081500_CIT0018","first-page":"185","article-title":"Type I interferon signature in Sj\u00f6gren\u2019s syndrome: pathophysiological and clinical implications","volume":"37","author":"Marketos","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025092206061081500_CIT0019","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025092206061081500_CIT0020","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025092206061081500_CIT0021","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Primary Sj\u00f6gren\u2019s Syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025092206061081500_CIT0022","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clim.2018.04.002","article-title":"Immune senescence, epigenetics and autoimmunity","volume":"196","author":"Ray","year":"2018","journal-title":"Clin Immunol"},{"key":"2025092206061081500_CIT0023","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1007\/s10067-019-04615-0","article-title":"Characterization of senescence biomarkers in rheumatoid arthritis: relevance to disease progression","volume":"38","author":"Petersen","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025092206061081500_CIT0024","doi-asserted-by":"publisher","first-page":"e2250353","DOI":"10.1002\/eji.202250353","article-title":"Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro","volume":"53","author":"Alamino","year":"2023","journal-title":"Eur J Immunol"},{"key":"2025092206061081500_CIT0025","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/annrheumdis-2014-206119","article-title":"Premature senescence of T-cell subsets in axial spondyloarthritis","volume":"75","author":"Fessler","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025092206061081500_CIT0026","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/art.39331","article-title":"Latent cytomegalovirus infection in rheumatoid arthritis and increased frequencies of cytolytic LIR-1+CD8+ T cells","volume":"68","author":"Rothe","year":"2016","journal-title":"Arthritis & Rheumatol"},{"key":"2025092206061081500_CIT0027","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00430-019-00608-7","article-title":"The hallmarks of CMV-specific CD8 T-cell differentiation","volume":"208","author":"van den Berg","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"2025092206061081500_CIT0028","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"2025092206061081500_CIT0029","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.cell.2008.03.039","article-title":"Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network","volume":"133","author":"Kuilman","year":"2008","journal-title":"Cell"},{"key":"2025092206061081500_CIT0030","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4049\/jimmunol.1801462","article-title":"Treatment of experimental autoimmune encephalomyelitis by sustained delivery of low-dose IFN-\u03b1","volume":"203","author":"Vasquez","year":"2019","journal-title":"J Immunol"},{"key":"2025092206061081500_CIT0031","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41467-017-02689-5","article-title":"Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"2025092206061081500_CIT0032","doi-asserted-by":"publisher","first-page":"E6301","DOI":"10.1073\/pnas.1515386112","article-title":"JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age","volume":"112","author":"Xu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025092206061081500_CIT0033","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/art.21353","article-title":"Modulation of CD28 expression with anti\u2013tumor necrosis factor \u03b1 therapy in rheumatoid arthritis","volume":"52","author":"Bryl","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025092206061081500_CIT0034","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00296-003-0374-4","article-title":"Therapy with infliximab decreases the CD4+CD28- T cell compartment in peripheral blood in patients with rheumatoid arthritis","volume":"24","author":"Pawlik","year":"2004","journal-title":"Rheumatol Int"},{"key":"2025092206061081500_CIT0035","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1172\/JCI133679","article-title":"Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy","volume":"130","author":"Liu","year":"2020","journal-title":"J Clin Invest"},{"key":"2025092206061081500_CIT0036","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"2025092206061081500_CIT0037","doi-asserted-by":"publisher","first-page":"e002139","DOI":"10.1136\/rmdopen-2021-002139","article-title":"Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database","volume":"8","author":"Seror","year":"2022","journal-title":"RMD Open"},{"key":"2025092206061081500_CIT0038","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025092206061081500_CIT0039","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025092206061081500_CIT0040","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2025092206061081500_CIT0041","doi-asserted-by":"publisher","first-page":"R210","DOI":"10.1186\/ar766","article-title":"The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis","volume":"5","author":"Pawlik","year":"2003","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxaf050\/64219573\/uxaf050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxaf050\/64219573\/uxaf050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxaf050\/64219573\/uxaf050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:06:21Z","timestamp":1758535581000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxaf050\/8248989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxaf050","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"type":"print","value":"0009-9104"},{"type":"electronic","value":"1365-2249"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"uxaf050"}}